4.6 Article

EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION

Journal

DEPRESSION AND ANXIETY
Volume 31, Issue 4, Pages 335-343

Publisher

WILEY
DOI: 10.1002/da.22253

Keywords

suicide/self-harm; depression; clinical trials; biological markers; mood disorders; antidepressants

Funding

  1. Evotec
  2. Janssen Pharmaceuticals
  3. Avanir
  4. NIMH Career Development Award [1K23 MH-094707]
  5. NIH National Center for Advancing Translational Sciences [UL1 TR000067]
  6. Icahn School of Medicine at Mount Sinai from AstraZeneca
  7. Brainsway
  8. Euthymics
  9. Neosync
  10. Roche
  11. CNS Response
  12. Otsuka
  13. Servier
  14. Sunovion
  15. AstraZeneca
  16. Bristol-Myers Squibb
  17. Naurex
  18. Genentech
  19. NIMH [RO1 MH-081870]
  20. Department of Veterans Affairs (VA)
  21. Brown Foundation, Inc.
  22. Career Development Award from NIMH [1K23MH100259]
  23. NARSAD

Ask authors/readers for more resources

Background: Preliminary evidence suggests intravenous ketamine has rapid effects on suicidal cognition, making it an attractive candidate for depressed patients at imminent risk of suicide. In the first randomized controlled trial of ketamine using an anesthetic control condition, we tested ketamine's acute effects on explicit suicidal cognition and a performance-based index of implicit suicidal cognition (Implicit Association Test; IAT) previously linked to suicidal behavior. Method: Symptomatic patients with treatment-resistant unipolar major depression (inadequate response to >= 3 antidepressants) were assessed using a composite index of explicit suicidal ideation (Beck Scale for Suicidal Ideation, Montgomery-Asberg Rating Scale suicide item, Quick Inventory of Depressive Symptoms suicide item) and the IAT to assess suicidality implicitly. Measures were taken at baseline and 24 hr following a single subanesthetic dose of ketamine (n = 36) or midazolam (n = 21), a psychoactive placebo agent selected for its similar, rapid anesthetic effects. Twenty four hours postinfusion, explicit suicidal cognition was significantly reduced in the ketamine but not the midazolam group. Results: Fifty three percent of ketamine-treated patients scored zero on all three explicit suicide measures at 24 hr, compared with 24% of the midazolam group (chi(2) = 4.6; P = .03). Implicit associations between self- and escape-related words were reduced following ketamine (P = .01; d = .58) but not midazolam (P = .68; d = .09). Ketamine-specific decreases in explicit suicidal cognition were largest in patients with elevated suicidal cognition at baseline, and were mediated by decreases in nonsuicide-related depressive symptoms. Conclusions: Intravenous ketamine produces rapid reductions in suicidal cognition over and above active placebo. Further study is warranted to test ketamine's antisuicidal effects in higher-risk samples.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available